Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

  • days left to enroll
  • participants needed
  • sponsor
    TransThera Sciences (Nanjing), Inc.
Updated on 19 June 2022


This is a first-in-human (FIH), multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.


The study will consist of two parts, dose escalation and dose expansion. A modified 3+3 design will be used to guide the dose escalation and the determination of the dose recommended for dose expansion (DRDE). A sentinel cohort comprising of one subject will be enrolled at a starting dose of 50 mg q.d. Subsequently, patients will be enrolled according to the standard 3+3 dose escalation design to determine the DRDE. Once the DRDE has been selected, TT-01488 of DRDE will be further tested in the dose expansion cohort to verify the safety and preliminary efficacy as observed in the dose escalation cohorts. A recommended Phase II dose (RP2D) may be determined based on the totality of safety, pharmacokinetics, and efficacy data from the dose escalation cohorts and dose expansion cohort.

Condition B-Cell Malignancies
Treatment TT-01488
Clinical Study IdentifierNCT05275504
SponsorTransThera Sciences (Nanjing), Inc.
Last Modified on19 June 2022


Yes No Not Sure

Inclusion Criteria

Men and women ≥ 18 years of age with histologically or cytologically confirmed R/R B-NHL, including but not limited to chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), Waldenström macroglobulinemia (WM), follicular lymphoma (FL), marginal zone lymphoma (MZL), diffuse large-b-cell lymphomas (DLBCL), and transformed lymphoma who failed or are intolerant to ≥ 1 prior standard of care regimens
Patients with prior treatment of BTK inhibitors are eligible
Patients with low grade lymphoma must be progressing and requiring treatment
Patients with CLL must have disease requiring treatment as specified in 2018 IWCLL Guidelines (Appendix 5)
Patients with B-cell NHL must have measurable disease per 2014 Lugano Classification (Appendix 6)
Patients with WM must have minimum serum immunoglobulin M (IgM) level of ≥ 2 times the upper limit of normal (ULN)
Body weight ≥ 40 kg
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
Adequate organ function, defined by the following laboratory parameters
Absolute neutrophil count (ANC) ≥ 750/ul, unless due to bone marrow involvement due to disease
Platelets ≥ 50,000/ul without transfusion within 7 days
Hemoglobin ≥ 80 mg/dl without transfusion within 7 days
Prothrombin time (PT) ≤ 1.5 × ULN
Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
Renal function
Creatinine clearance ≥ 60 mL/min estimated glomerular filtration rate based on Cockcroft-Gault formula or 24-hour urine collection
Liver function
Total bilirubin ≤ 1.5 × ULN (unless due to Gilbert's disease)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN unless disease-related
Agreement to use contraception during the study and until at least 6 months after the
last dose of study drug if sexually active and able to bear children
Willing and able to participate in all required evaluations and procedures in the study protocol including swallowing tablets without difficulty
Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations)

Exclusion Criteria

Women who are pregnant or lactating
Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 2 years or which will not limit survival to < 2 years (Note: these cases must be discussed with the Medical Monitor and/or Investigator)
A life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of TT-01488, or put the study outcomes at undue risk
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or significant screening ECG abnormalities including left bundle branch block, 2nd degree AV block type II, 3rd degree block, bradycardia, and corrected QT interval using Fridericia's Formula (QTcF) > 470 msec, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
Any immunotherapy, , radiotherapy (limited-field radiation for palliation within 7 days), or experimental therapy within 4 weeks, or 5-half lives for chemotherapy and small molecule agents (whichever is shorter), before first dose of study drug (corticosteroids for disease-related symptoms allowed but require 1-week washout before study drug administration)
History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days or with any of the
Active graft versus host disease (GvHD)
Cytopenias from incomplete blood cell count recovery post-transplant
Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity > Grade 1 from CAR-T therapy
Ongoing immunosuppressive therapy
Concomitant use of prohibited medications(Section 6.4.2), including
Therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants
Medications with known risk to cause QT prolongation or Torsades de pointes
Strong CYP3A inhibitors and inducers (must be discontinued for at least 14 days or 5 half-lives, whichever is longer, before study treatment)
Proton pump inhibitors, histamine-2 blockers (H2 blockers), and locally acting antacids (Note: For patients who are dependent upon this class of medications, patients may be considered after consulting with the study investigator and Sponsor. See Section 6.4.2 for more details)
Central nervous system involvement by lymphoma
Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy, including radiation
Known history of Human Immunodeficiency Virus (HIV) or active infection with Cytomegalovirus (CMV), Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV), or any uncontrolled active systemic infection
Major surgery within 4 weeks before first dose of study drug
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note